Código QR (código de barras bidimensional)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy

Abstract Background Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs. Methods This prospective, open-label observational study...

ver descrição completa

Na minha lista:
Principais autores: Aliya Jaber, Meera Patel, Andrew Sylvester, Mary Yarussi, J. Tamar Kalina, Jason P. Mendoza, Robin L. Avila, Matthew A. Tremblay
Formato: Artigo
Idioma:Inglês
Publicado em: Adis, Springer Healthcare 2023-02-01
coleção:Neurology and Therapy
Assuntos:
COVID-19
Dimethyl fumarate
Interferon beta
Multiple sclerosis
Natalizumab
Ocrelizumab
Acesso em linha:https://doi.org/10.1007/s40120-023-00448-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados